SYK vs TMCI
SYK: A diversified global MedTech leader providing surgical instruments, robotics, and advanced clinical technologies to enhance patient recovery and healthcare outcomes. TMCI: Treace Medical Concepts is a specialized medical technology company pioneering 3D bunion correction systems and comprehensive foot and ankle surgical solutions.
Side-by-side fundamentals
| Metric | SYK | TMCI | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $297.60 | $4.14 | |
| Market cap | $114.2B | $269M | |
| P/E as of 2026-10-21 | 30.84 | n/a | |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | 2.85 | n/a | |
| Net margin FY2025, SEC XBRL | +12.9% | -27.7% | SYK higher |
| Gross margin FY2025, SEC XBRL | +64.0% | +79.8% | TMCI higher |
| Operating margin FY2025, SEC XBRL | +19.5% | -25.5% | SYK higher |
| ROE FY2025, SEC XBRL | +14.5% | -67.6% | SYK higher |
| ROA FY2025, SEC XBRL | +6.8% | -31.0% | SYK higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.60 | 0.87 | SYK lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +11.2% | +1.6% | SYK higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +14.5% | TMCI higher |
| Dividend yield as of 2026-09-02 | +1.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 8 | 0 | SYK higher |
| Beta as of 2026-09-02 | 0.55 | 1.33 | |
| 1-year return as of 2026-10-21 close | -21.6% | -40.4% | SYK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.